Johnson & Johnson has achieved a Q3 profit of $3.393 billion, with sales of $20.35 billion for the three months ending September 30th.
Topping the general consensus, the company has raised its full year outlook to an adjusted EPS of $8.13 to $8.18, with expected sales of $81.0 billion to $81.4 billion.
Alex Gorsky, CEO and Chairman said, “We are pleased with our strong third-quarter performance, which reflects continued above-market growth in our pharmaceutical business, accelerating sales momentum in our consumer business and consistent progress in our medical devices business.
“I’m confident that with our collaborative and inspired J&J colleagues around the world, unique broad-based business model and strategic investments in innovation, we are well positioned for success today and into the future.”
Worldwide consumer sales rose 1.8 percent year on year to $3.4 billion. Domestic sales increased 6.6 percent while international sales decreased 1.3 percent due to an operational increase of 3.7 percent and a negative currency impact of 5 percent.